Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025 (Event Date)
Reporting Period: The filing reports on events occurring in September 2025 regarding executive leadership changes.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
- Severance Pay: $212,500 (compensation continuation over six months).
- Performance Bonus: $85,000 (contingent on a successful spin-off, out-licensing, or similar transaction relating to Nova Cell prior to October 31, 2025).
- Benefits: COBRA premiums for six months commencing October 2025.
- Consulting Fee: $250 per hour (maximum 20 hours per month) for a six-month term.
Material Changes
The primary material change is the elimination of the Chief Legal Officer position and the termination of Ms. Wendy Pizarro Campbell's employment, effective October 17, 2025.
- Reason for Change: Part of ongoing cost-reduction and operating-efficiency initiatives to align senior leadership with the company's size, stage of development, and available resources.
- Succession: Andrew Jackson, Chief Financial Officer, has been appointed as Corporate Secretary effective October 17, 2025.
- Dispute Status: The company explicitly states the decision was not due to any disagreement regarding operations, policies, or practices.
Outlook, Risks, and Contingencies
Management Commentary: The leadership reduction is a strategic move to improve operational efficiency. The company is transitioning Ms. Campbell from an executive officer to a consultant.
Contingencies:
- Revocation Period: The separation agreement becomes effective only after a seven-business-day revocation period following September 17, 2025.
- Transaction Contingency: The $85,000 bonus is strictly contingent on a specific transaction involving "Nova Cell" occurring before October 31, 2025.
- Consulting Term: The consulting agreement is for an initial six-month term and may be terminated early by either party without reason.
Investor Verification Checklist
- Verify the status of the "Nova Cell" asset and the likelihood of a spin-off or out-licensing transaction by October 31, 2025, to assess the probability of the $85,000 bonus payout.
- Confirm the total cash outflow impact of the severance package ($212,500) and consulting fees against the company's current cash runway.
- Review the full text of Exhibits 10.1 and 10.2 for any additional restrictive covenants or non-compete clauses not detailed in the summary.
- Monitor future filings for updates on the company's cost-reduction initiatives and whether further leadership changes are planned.